Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Espíndola, Reinaldo
• dc.contributor.author Sorlí, Luisa
• dc.contributor.author ARTHR-IS Group
• dc.date.accessioned 2024-05-22T07:24:10Z
• dc.date.available 2024-05-22T07:24:10Z
• dc.date.issued 2023
• dc.description.abstract Background: The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres. Methods: This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables. Results: The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI. Conclusions: This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI.
• dc.description.sponsorship This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). R.E., L.S, O.M., R.E.-S., J.L.-T., J.P., J.R.-B. and M.D.del T. are members of the Spanish Network for Research in Infectious Diseases (REIPI), supported by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0005; 0009; 0011; 0015), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014–2020. M.W.P. was partly supported by the German Research Foundation (GRK 2723, project number 444711651). The funders did not influence the analysis or decision to publish; GlaxoSmithKline Biologicals SA had the opportunity to review a version of this manuscript for factual accuracy; the authors are solely responsible for the final content and interpretation.
• dc.format.mimetype application/pdf
• dc.identifier.citation Espíndola R, Vella V, Benito N, Mur I, Tedeschi S, Zamparini E, et al. Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study. J Hosp Infect. 2023 Dec;142:9-17. DOI: 10.1016/j.jhin.2023.09.012
• dc.identifier.doi http://dx.doi.org/10.1016/j.jhin.2023.09.012
• dc.identifier.issn 0195-6701
• dc.identifier.uri http://hdl.handle.net/10230/60213
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof J Hosp Infect. 2023 Dec;142:9-17
• dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/115523
• dc.rights © 2023 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Healthcare utilization
• dc.subject.keyword Incidence
• dc.subject.keyword Prosthetic joint infection
• dc.subject.keyword Staphylococcus aureus
• dc.subject.keyword Treatment failure
• dc.title Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion